Calamos Advisors LLC Invests $1.22 Million in Palvella Therapeutics, Inc. $PVLA

Calamos Advisors LLC purchased a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,804 shares of the company’s stock, valued at approximately $1,222,000.

A number of other institutional investors also recently bought and sold shares of the business. Jennison Associates LLC increased its holdings in shares of Palvella Therapeutics by 262.4% in the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after acquiring an additional 280,573 shares during the last quarter. Profund Advisors LLC purchased a new stake in Palvella Therapeutics during the fourth quarter worth approximately $608,000. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 13.3% in the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after purchasing an additional 65,960 shares in the last quarter. Emerald Advisers LLC acquired a new position in Palvella Therapeutics in the first quarter valued at approximately $20,131,000. Finally, Lisanti Capital Growth LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at approximately $4,341,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PVLA has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Palvella Therapeutics Trading Down 2.8%

NASDAQ:PVLA opened at $147.77 on Friday. Palvella Therapeutics, Inc. has a 12-month low of $28.19 and a 12-month high of $161.38. The stock’s 50 day simple moving average is $124.54 and its 200-day simple moving average is $115.00. The firm has a market cap of $2.12 billion, a P/E ratio of -35.44 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Research analysts forecast that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.